The BioMe team behind the development of a revolutionary pill (from left) Matthias Thurner, Agnieszka Chomka, Soren Thomsen and Patrick Albers stand in front of the Radcliffe Camera
The article highlights how "a hi-tech pill being developed by a team of Oxford scientists could revolutionise the way doctors test for some diseases".
Further, "with pills expected to cost £2 each, compared to £800 for an endoscopy session, it could herald a breakthrough for the cash-strapped NHS."
BioMe was a former finalist at Venturefest's funding event for investor-ready entrepreneurs, Pitchfest, and has also been shortlisted for The Oxford Trust Enterprise Awards 2016.
Read more
Latest news
Research, industry, and AGI
A transfer of knowledge to industry is a good thing: One purpose of a university is to benefit society by disseminating knowledge, and one way this can be done is by commercialising research. Universities and research institutions are a dynamo for entrepreneurship, and for innovation in large companies. READ MORE
For success in product development – start at square zero
When it comes to the commercial success of a technology-led product, there are a number of factors that come into play along the development journey. Have the regulatory requirements been met? Can the design be produced at a viable cost? Is it possible to ensure the quality of the manufacturing process? The list goes on. READ MORE
The not-so-small matter of scale: Making it big in microfluidics
Microfluidics is a key technology enabling the development of rapid in-vitro diagnostics (IVD). With applications including COVID-19 testing, cardiac arrest assessment and STD screening, decentralised rapid diagnostics are shaping up to be a major part of the future of healthcare and wellness monitoring. READ MORE
Make connections that lead to new investments, new businesses and new ideas in the high-tech sector in Oxfordshire.